Financial data tables

Arcturus Therapeutics (ARCT) figures from its financial statements (company filings via Financial Modeling Prep), in US dollars; non-US reporters are converted to US dollars. Periods carry the company's own fiscal quarter and year, as its filings name them, with the date each period ended. Source filings are on the Filings tab.

Arcturus Therapeutics quarterly results
PeriodRevenueGross profitOperating incomeNet incomeDiluted EPSGross marginOperating margin
Q3 FY2026 (ended Sep 30, 2026)$18.0M$18.0M-$9.0M-$7.0M-$0.26100.0%-50.2%
Q2 FY2026 (ended Jun 30, 2026)$3.0M$3.0M-$26.0M-$24.0M-$0.84100.0%-863.3%
Q1 FY2026 (ended Mar 31, 2026)$1.0M$0.0M-$30.0M-$27.0M-$0.95-7.9%-4882.0%
Q4 FY2025 (ended Dec 31, 2025)$3.0M$3.0M-$31.0M-$29.0M-$1.05100.0%-1016.1%
Q3 FY2025 (ended Sep 30, 2025)$17.0M$14.0M-$17.0M-$13.0M-$0.4980.5%-96.3%
Q2 FY2025 (ended Jun 30, 2025)$25.0M$25.0M-$12.0M-$9.0M-$0.34100.0%-47.4%
Q1 FY2025 (ended Mar 31, 2025)$29.0M$29.0M-$17.0M-$14.0M-$0.52100.0%-57.3%
Q4 FY2024 (ended Dec 31, 2024)$21.0M$21.0M-$33.0M-$30.0M-$1.11100.0%-159.0%
Arcturus Therapeutics quarterly cash flow
PeriodOperating cash flowCapital expendituresFree cash flowShare repurchasesDividends paid
Q3 FY2026 (ended Sep 30, 2026)-$7.0M$0.0M-$7.0M$0.0M$0.0M
Q2 FY2026 (ended Jun 30, 2026)-$20.0M$0.0M-$20.0M$0.0M$0.0M
Q1 FY2026 (ended Mar 31, 2026)-$19.0M$0.0M-$19.0M$0.0M$0.0M
Q4 FY2025 (ended Dec 31, 2025)-$16.0M$0.0M-$16.0M$0.0M$0.0M
Q3 FY2025 (ended Sep 30, 2025)-$17.0M$0.0M-$17.0M$0.0M$0.0M
Q2 FY2025 (ended Jun 30, 2025)-$6.0M$0.0M-$6.0M$0.0M$0.0M
Q1 FY2025 (ended Mar 31, 2025)-$35.0M$0.0M-$35.0M$0.0M$0.0M
Q4 FY2024 (ended Dec 31, 2024)$0.0M$0.0M$0.0M$0.0M$0.0M
Arcturus Therapeutics balance sheet
PeriodTotal assetsCash and equivalentsShort-term investmentsTotal debtTotal equity
Q3 FY2026 (ended Sep 30, 2026)$215.0M$185.0M$0.0M$22.0M$169.0M
Q2 FY2026 (ended Jun 30, 2026)$224.0M$191.0M$0.0M$23.0M$172.0M
Q1 FY2026 (ended Mar 31, 2026)$245.0M$211.0M$0.0M$24.0M$191.0M
Q4 FY2025 (ended Dec 31, 2025)$271.0M$231.0M$0.0M$25.0M$214.0M
Arcturus Therapeutics revenue by segment
SegmentQ2 FY2026 (ended Jun 30, 2026)Q1 FY2026 (ended Mar 31, 2026)Q4 FY2025 (ended Dec 31, 2025)Q3 FY2025 (ended Sep 30, 2025)
Grant$2.0M$1.0M$4.0M$3.0M
Collaboration Revenue$1.0M$1.0M$3.0M$14.0M
Arcturus Therapeutics employees
YearEmployees
2025106
2024174
2023180
2022170
2021177
2020118

Arcturus Therapeutics (ARCT) reported revenue of $18.00M in Q3 2026, with Grant its largest revenue segment at 70%.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites